Tela Bio Inc (TELA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tela Bio Inc (TELA) has a cash flow conversion efficiency ratio of 0.591x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.38 Million) by net assets ($-15.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Tela Bio Inc worth for the company's overall valuation and market capitalisation.
Tela Bio Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Tela Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tela Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tela Bio Inc ranked by their cash flow conversion efficiency. See TELA debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Indo Acidatama Tbk
JK:SRSN
|
0.060x |
|
Baylin Technologies Inc
TO:BYL
|
-0.042x |
|
Alchera Inc.
KQ:347860
|
-0.197x |
|
Tidehold Development Co Ltd
TW:9902
|
0.079x |
|
Triller Group Inc. Common Stock
NYSE:ILLR
|
0.013x |
|
Petershill Partners PLC
LSE:PHLL
|
0.014x |
|
Arribatec Solutions ASA
OL:ARR
|
-0.054x |
|
Banswara Syntex Limited
NSE:BANSWRAS
|
0.034x |
Annual Cash Flow Conversion Efficiency for Tela Bio Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Tela Bio Inc from 2017 to 2025. View current stock price of Tela Bio Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.31 Million | $-28.22 Million | -4.470x | -205.82% |
| 2024-12-31 | $28.46 Million | $-41.59 Million | -1.462x | +32.45% |
| 2023-12-31 | $18.88 Million | $-40.86 Million | -2.164x | +24.03% |
| 2022-12-31 | $14.30 Million | $-40.75 Million | -2.849x | -88.12% |
| 2021-12-31 | $20.10 Million | $-30.43 Million | -1.514x | -203.54% |
| 2020-12-31 | $49.03 Million | $-24.46 Million | -0.499x | +39.49% |
| 2019-12-31 | $30.96 Million | $-25.52 Million | -0.824x | -670.38% |
| 2018-12-31 | $-137.86 Million | $-19.92 Million | 0.145x | -4.49% |
| 2017-12-31 | $-108.17 Million | $-16.37 Million | 0.151x | -- |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more